Stay updated with breaking news from Aptose Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cabaletta Bio (NASDAQ:CABA – Get Free Report) and Aptose Biosciences (NASDAQ:APTO – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation. Volatility and Risk Cabaletta Bio has a […]
Cabaletta Bio (NASDAQ:CABA – Get Free Report) and Aptose Biosciences (NASDAQ:APTO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership. Analyst Recommendations This is a breakdown of […]
Aptose Biosciences (NASDAQ:APTO – Get Free Report) and Sutro Biopharma (NASDAQ:STRO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk. Risk & Volatility Aptose Biosciences has a […]
Aptose Biosciences Inc. (TSE:APS – Get Rating) (NASDAQ:APTO) – Research analysts at HC Wainwright decreased their Q2 2023 earnings estimates for shares of Aptose Biosciences in a research report issued on Monday, June 12th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings of ($3.07) per share for the quarter, […]
Aptose Biosciences Inc. (TSE:APS – Get Rating) (NASDAQ:APTO) – Stock analysts at HC Wainwright issued their Q2 2023 earnings estimates for shares of Aptose Biosciences in a report issued on Tuesday, May 9th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will post earnings per share of ($0.20) for the quarter. The consensus […]